Mood Disorders
|
0.390 |
GeneticVariation
|
group |
BEFREE |
According to our meta-analysis, TPH2 polymorphisms show strongest associations with mood disorders, suicide (attempt) and schizophrenia.
|
29775696 |
2018 |
Mood Disorders
|
0.390 |
Biomarker
|
group |
BEFREE |
The main conclusions of this review are as follows: (i) the brain 5-HT deficiency contributes to the mechanism underlying SAD, (ii) TPH2 is involved in the regulation of some kinds of genetically defined affective disorders and (iii) the activation of 5-HT synthesis with exogenous l-tryptophan alone or in combination with light therapy could be effective in SAD treatment.
|
26167977 |
2015 |
Mood Disorders
|
0.390 |
Biomarker
|
group |
BEFREE |
We did not find evidence for a role of the TPH2 microdeletion in the pathoetiology of affective disorders.
|
24754353 |
2014 |
Mood Disorders
|
0.390 |
Biomarker
|
group |
PSYGENET |
We did not find evidence for a role of the TPH2 microdeletion in the pathoetiology of affective disorders.
|
24754353 |
2014 |
Mood Disorders
|
0.390 |
AlteredExpression
|
group |
BEFREE |
Genetic variation in human tryptophan hydroxylase 2 (TPH2) influences TPH enzymatic activity and is associated with emotion-related traits and mood disorders.
|
22649797 |
2012 |
Mood Disorders
|
0.390 |
Biomarker
|
group |
PSYGENET |
Genetic variation in human tryptophan hydroxylase 2 (TPH2) influences TPH enzymatic activity and is associated with emotion-related traits and mood disorders.
|
22649797 |
2012 |
Mood Disorders
|
0.390 |
Biomarker
|
group |
PSYGENET |
Findings from psychophysiological and functional imaging studies are indicative of various TPH2 polymorphisms directly influencing serotonergic function and thus impacting on mood disorders and on the response to antidepressant treatment.
|
21257271 |
2011 |
Mood Disorders
|
0.390 |
Biomarker
|
group |
PSYGENET |
Aberrant serotonergic functioning is strongly implicated in hyperphagia in PWS, and females with TPH2 T alleles may be at higher risk for affective or mood disorders.
|
21418060 |
2011 |
Mood Disorders
|
0.390 |
GeneticVariation
|
group |
BEFREE |
Findings from psychophysiological and functional imaging studies are indicative of various TPH2 polymorphisms directly influencing serotonergic function and thus impacting on mood disorders and on the response to antidepressant treatment.
|
21257271 |
2011 |
Mood Disorders
|
0.390 |
Biomarker
|
group |
PSYGENET |
More comprehensive study of TPH2 genetics is needed to increase the clinical value of the enzyme as a predictor of affective disorder risk and efficacy of antidepressant drugs.
|
20874521 |
2010 |
Mood Disorders
|
0.390 |
Biomarker
|
group |
BEFREE |
More comprehensive study of TPH2 genetics is needed to increase the clinical value of the enzyme as a predictor of affective disorder risk and efficacy of antidepressant drugs.
|
20874521 |
2010 |
Mood Disorders
|
0.390 |
GeneticVariation
|
group |
BEFREE |
No association was detected between the rs4131347 (-C8347G) SNP in the promoter region of the TPH2 gene and mood disorders, suicidal behavior or monoamine function.
|
17604842 |
2008 |
Mood Disorders
|
0.390 |
Biomarker
|
group |
BEFREE |
Haplotype-based analysis of TPH2 in patients with UP and BP disorder and controls from northern Swedish descent provides preliminary evidence for protective association in both disorders and thus supports a central role for TPH2 in the pathogenesis of affective disorders.
|
17015812 |
2006 |
Mood Disorders
|
0.390 |
Biomarker
|
group |
LHGDN |
Haplotype-based analysis of TPH2 in patients with UP and BP disorder and controls from northern Swedish descent provides preliminary evidence for protective association in both disorders and thus supports a central role for TPH2 in the pathogenesis of affective disorders.
|
17015812 |
2006 |
Mood Disorders
|
0.390 |
Biomarker
|
group |
BEFREE |
TPH2, rather than TPH1, has now become a candidate gene for 5-HT-related affective disorders.
|
15968084 |
2005 |